ERBB2 and breast carcinoma: Common adverse reactions associated with the combination of T-DM1 and radiotherapy in the treatment of HER-2-positive breast cancer include radiation-induced brain necrosis, hematologic toxicity (particularly thrombocytopenia), skin damage, cardiotoxicity, and pulmonary toxicity [18, 25, 38].